Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCLUDE phase III trial of rectal cobitolimod for left-sided ulcerative colitis
NL-OMON51406Phase 3Not yet recruiting
- Sponsor
- InDex Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cobitolimod in autoimmune colitis (5 arms), sponsored by InDex Pharmaceuticals. Primary endpoints: Clinical remission at induction week 6 and Clinical remission at maintenance week 45. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON51406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51406.